Douglas Adkins

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

William D. Tap, Robin L. Jones, Brian A. Van Tine et al. · The Lancet · 2016 · 588 citations

Medicine, Oncology, Pharmacology +9

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Ravindra Uppaluri, Robert I. Haddad, Yungan Tao et al. · New England Journal of Medicine · 2025 · 266 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025

A. Dimitrios Colevas, Anthony J. Cmelak, David G. Pfister et al. · Journal of the National Comprehensive Cancer Network · 2025 · 133 citations

Medicine, Oncology, Radiation Oncology +17

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

Nilofer S. Azad, Anthony B. El-Khoueiry, Jun Yin et al. · Oncotarget · 2017 · 93 citations · Full text

Medicine, Oncology, Pharmacology +11

A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma

Kristen N. Ganjoo, Lee D. Cranmer, James E. Butrynski et al. · Oncology · 2011 · 84 citations

Pharmacy, Pharmacokinetics, Pharmacology +14